Intrinsic radiation resistance of mesenchymal cancer stem cells and implications for treatment response in a murine sarcoma model

Danish Medical Journal

Volumn 59, Issue 2, 2012, Pages

  D'Andrea, Filippo Peder ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 1; NICOTINAMIDE; PIMONIDAZOLE;

ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOLOGY; IRRADIATION; NONHUMAN; OXIMETRY; OXYGEN ELECTRODE; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ANIMAL; APOPTOSIS; CANCER TRANSPLANTATION; DNA DAMAGE; GENETICS; MESENCHYMAL STROMA CELL; MOUSE; NUDE MOUSE; PHYSIOLOGY; RADIATION DOSE; RADIATION EXPOSURE;

ANIMALS; APOPTOSIS; DNA DAMAGE; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; SARCOMA;

EID: 84873157525     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Turesson I. The progression rate of late radiation effects in normal tissue and its impact on dose-response relationships. Radiotherapy and Oncology 1989;15:217-26.
2. Rodemann HP, Bamberg M. Cellular basis of radiationinduced fibrosis. Radiotherapy and Oncology 1995;35:83-90.
3. Shafiq J, Barton M, Noble D, Lemer C, Donaldson LJ. An international review of patient safety measures in radiotherapy practice. Radiother Oncol 2009;92:15-21.
4. Korreman S, Rasch C, McNair H et al. The European Society of Therapeutic Radiology and Oncology-European Institute of Radiotherapy (ESTRO-EIR) report on 3D CTbased in-room image guidance systems: A practical and technical review and guide. Radiotherapy and Oncology 2010;94:129-44.
5. Wouters BG, Begg AC. Irradiation-induced damage and the DNA damage reaponse. In: Joiner M, van der Kogel A, editors. Basic Clinical Radiobiology. 4th Edition. London: Hodder Arnold, 2011;11-26.
6. Dantzer F, de Murcia G, Menissier-de Murcia J, Nasheuer HP, Vonesch JL. Functional association of poly (ADP-ribose) polymerase with DNA polymerase α-primase complex: A link between DNA strand break detection and DNA replication. Nucleic Acids Res 1998;26:1891-8.
7. Xu Y, Baltimore D. Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes & Development 1996;10:2401-10.
8. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M, Jeggo PA. ATM and DNA-PK Function Redundantly to Phosphorylate H2AX after Exposure to Ionizing Radiation. Cancer Res 2004;64:2390-6.
9. Toshiyuki M, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
10. Chipuk JE, Kuwana T, Bouchier-Hayes L et al. Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis. Science 2004;303:1010-4.
11. Wade Harper J, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
12. Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 2008;9:297-308.
13. Rassool FV, Gaymes TJ, Omidvar N et al. Reactive Oxygen Species, DNA Damage, and Error-Prone Repair: A Model for Genomic Instability with Progression in Myeloid Leukemia? Cancer Res 2007;67:8762-71.
14. Kinsella TJ. Coordination of DNA Mismatch Repair and Base Excision Repair Processing of Chemotherapy and Radiation Damage for Targeting Resistant Cancers. Clin Cancer Res 2009;15:1853-9.
15. Ikejima M, Noguchi S, Yamashita R et al. The zinc fingers of human poly (ADP-ribose) polymerase are differentially required for the recognition of DNA breaks and nicks and the consequent enzyme activation. Other structures recognize intact DNA. J Biol Chem 1990;265:21907-13.
16. Herceg Z, Wang ZQ. Functions of poly (ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res 2001;477:97-110.
17. Li X, Heyer WD. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res 2008;18:99-113.
18. Mladenov E, Iliakis G. Induction and repair of DNA double strand breaks: The increasing spectrum of nonhomologous end joining pathways. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2011;711:61-72.
19. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 Protein in the Cellular Response to DNA Damage. Cancer Res 1991;51:6304-11.
20. Shieh SY, Ikeda M, Taya Y, Prives C. DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2. Cell 1997;91:325-34.
21. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO 1993;12:461-8.
22. Ouelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
23. Zhang Y, Xiong Y. Mutations in Human ARF Exon 2 Disrupt Its Nucleolar Localization and Impair Its Ability to Block Nuclear Export of MDM2 and p53. Molecular Cell 1999;3:579-91.
24. Herceg Z, Wang ZQ. Failure of Poly (ADP-Ribose) Polymerase Cleavage by Caspases Leads to Induction of Necrosis and Enhanced Apoptosis. Mol Cell Biol 1999;19:5124-33.
25. Ha HC, Snyder SH. Poly (ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proceedings of the National Academy of Sciences 1999;96:13978-82.
26. Berger NA. Poly (ADP-Ribose) in the Cellular Response to DNA Damage. Radiat Res 1985;101:4-15.
27. Earnshaw WC. Apoptosis: lessons from in vitro systems. Trends in Cell Biology 1995;5:217-20.
28. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50.
29. Shay JW, Wright WE. Telomeres and telomerase in normal and cancer stem cells. FEBS Letters 2010;584:3819-25.
30. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone Marrow Stromal Stem Cells: Nature, Biology, and Potential Applications. Stem Cells 2001;19:180-92.
31. Chamberlain G, Fox J, Ashton B, Middleton J. Concise Review: Mesenchymal Stem Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for Homing. Stem Cells 2007;25:2739-49.
32. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99.
33. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
34. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
35. Baba T, Convery PA, Matsumura N et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2008;28:209-18.
36. Suva ML, Riggi N, Stehle JC et al. Identification of Cancer Stem Cells in Ewing's Sarcoma. Cancer Res 2009;69:1776-81.
37. Terry J, Nielsen T. Expression of CD133 in Synovial Sarcoma. Applied Immunohistochemistry & Molecular Morphology 2010;18
38. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences 2003;100:3983-8.
39. Dittfeld C, Dietrich A, Peickert S et al. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116. Radiother Oncol 2009;92:353-61.
40. Strauss R, Li Z-Y, Liu Y et al. Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity. PLoS ONE 2011;6
41. -Phenotype with Poor Prognosis in Early-Stage Breast Cancer. Neoplasia 2009;11:987-1002.
42. Charafe-Jauffret E, Ginestier C, Iovino F et al. Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature. Cancer Res 2009;69:1302-13.
43. Zeppernick F, Ahmadi R, Campos B et al. Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients. Clin Cancer Res 2008;14:123-9.
44. Eramo A, Lotti F, Sette G et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2007;15:504-14.
45. Hanahan D, Weinberg RA. The Hallmarks of Cancer Review. Cell 2000;100:57-70.
46. Bernhard EJ. Interventions that induce modifications in the tumor microenvironment. Cancer/Radiotherapie 2011;15:376-82
47. Hall EJ, Bedford JS, Oliver R. Extreme Hypoxia; its Effect on the Survival of Mammalian Cells Irradiated at High and Low Dose-rates. Br J Radiol 1966;39:302-7.
48. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The Concentration of Oxygen Dissolved in Tissues at the Time of Irradiation as a Factor in Radiotherapy. Br J Radiol 1953;26:638-48.
49. Nordsmark M, Alsner J, Keller J et al. Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations. Br J Cancer 2001;84:1070-5.
50. Diehn M, Cho RW, Lobo NA et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780-3.
51. Horsman MR. Measurement of tumor oxygenation. International Journal of Radiation Oncology*Biology*Physics 1998;42:701-4.
52. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Seminars in Radiation Oncology 2004;14:198-206.
53. Kopp HG, Avecilla ST, Hooper AT, Rafii S. The Bone Marrow Vascular Niche: Home of HSC Differentiation and Mobilization. Physiology 2005;20:349-56.
54. Calabrese C, Poppleton H, Kocak M et al. A Perivascular Niche for Brain Tumor Stem Cells. Cancer Cell 2007;11:69-82.
55. Keith B, Simon MC. Hypoxia-Inducible Factors, Stem Cells, and Cancer. Cell 2007;129:465-72.
56. McCord AM, Jamal M, Williams ES, Camphausen K, Tofilon PJ. CD133+ Glioblastoma Stem-like Cells are Radiosensitive with a Defective DNA Damage Response Compared with Established Cell Lines. Clin Cancer Res 2009;15:5145-53.
57. Jamal M, Rath BH, Williams ES, Camphausen K, Tofilon PJ. Microenvironmental Regulation of Glioblastoma Radioresponse. Clin Cancer Res 2010;16:6049-59.
58. Yu J, Vodyanik MA, Smuga-Otto K et al. Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells. Science 2007;318:1917-20.
59. Takahashi K, Tanabe K, Ohnuki M et al. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell 2007;131:861-72.
60. Zhou H, Wu S, Joo JY et al. Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins. Cell Stem Cell 2009;4:381-4.
61. Covello KL, Kehler J, Yu H et al. HIF-2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes & Development 2006;20:557-70.
62. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2α Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional Activity. Cancer Cell 2007;11:335-47.
63. Taub R, Kirsch I, Morton C et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proceedings of the National Academy of Sciences 1982;79:7837-41.
64. Bodnar AG, Ouellette M, Frolkis M et al. Extension of Life-Span by Introduction of Telomerase into Normal Human Cells. Science 1998;279:349-52.
65. Simonsen JL, Rosada C, Serakinci N et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 2002;20:592-6.
66. Serakinci N, Guldberg P, Burns JS et al. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 2004;23:5095-8.
67. Abdallah BM, Haack-Sorensen M, Burns JS et al. Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite [corrected] extensive proliferation. Biochem Biophys Res Commun 2005;326:527-38.
68. Burns JS, Abdallah BM, Shroder HD, Kassem M. The histopathology of a human mesenchymal stem cell experimental tumor model: support for an hMSC origin for Ewing's sarcoma? Histol Histopathol 2008;23:1229-40.
69. Gronbak K, Ralfkiaer U, Dahl C et al. Frequent hypermethylation of DBC1 in malignant lymphoproliferative neoplasms. Mod Pathol 2008;21:632-8.
70. Burns JS, Abdallah BM, Guldberg P, Rygaard J, Schroder HD, Kassem M. Tumorigenic Heterogeneity in Cancer Stem Cells Evolved from Long-term Cultures of Telomerase-Immortalized Human Mesenchymal Stem Cells. Cancer Res 2005;65:3126-35.
71. Larsen KH, Frederiksen CM, Burns JS, Abdallah BM, Kassem M. Identifying a molecular phenotype for bone marrow stromal cells with in vivo bone-forming capacity. J Bone Miner Res 2010;25:796-808.
72. Offersen BV, Borre M, Overgaard J. Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density. European Journal of Cancer 2003;39:881-90.
73. Zips D, Le K, Yaromina A et al. Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas. Radiother Oncol 2009;92:405-10.
74. Airley R, Loncaster J, Davidson S et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 2001;7:928.
75. El-Guendy N, Zhao Y, Gurumurthy S, Burikhanov R, Rangnekar VM. Identification of a Unique Core Domain of Par-4 Sufficient for Selective Apoptosis Induction in Cancer Cells. Mol Cell Biol 2003;23:5516-25.
76. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22:205-22.
77. Gondi CS, Kandhukuri N, Dinh DH, Gujrati M, Rao JS. Downregulation of uPAR and uPA activates caspase mediated apoptosis, inhibits the PI3k/AKT pathway. Int J Oncol 2007;31:19.
78. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463.
79. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane Type I Matrix Metalloproteinase Usurps Tumor Growth Control Imposed by the Three-Dimensional Extracellular Matrix. Cell 2003;114:33-45.
80. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells. Cell 2005;120:303-13.
81. Sauve AA. NAD+ and Vitamin B3: From Metabolism to Therapies. J Pharmacol Exp Ther 2008;324:883-93.
82. Kim J, Hong S, Lim E et al. Expression of nicotinamide Nmethyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res 2009;28:20.
83. Dalby MJ, Gadegaard N, Tare R et al. The control of human mesenchymal cell differentiation using nanoscale symmetry and disorder. Nature materials 2007;6:997-1003.
84. Trieb K, Sztankay A, Amberger A, Lechner H, Grubeck-Loebenstein B. Hyperthermia inhibits proliferation and stimulates the expression of differentiation markers in cultured thyroid carcinoma cells. Cancer Letters 1994;87:65-71.
85. Sharif-Khatibi L, Kariminia A, Khoei S, Goliaei B. Hyperthermia induces differentiation without apoptosis in permissive temperatures in human erythroleukaemia cells. Int J Hyperthermia 2007;23:645-55.
86. Norgaard R, Kassem M, Rattan SIS. Heat Shock-Induced Enhancement of Osteoblastic Differentiation of hTERTImmortalized Mesenchymal Stem Cells. Ann NY Acad Sci 2006;1067:443-7.
87. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;2:296-313.